Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Lung Cancer
Non-small Cell Lung Cancer Metastatic
Non-small Cell Lung Cancer Stage IIIB
Stage IV Non-small Cell Lung Cancer
EGFR Negative Non-Small Cell Lung Cancer

Interventions

DRUG: Ceritinib
DRUG: Docetaxel

Sponsor

H. Lee Moffitt Cancer Center and Research Institute